Is Corcept Therapeutics Stock a Good Investment?
Corcept Therapeutics Investment Advice | CORT |
- Examine Corcept Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Corcept Therapeutics' leadership team and their track record. Good management can help Corcept Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Corcept Therapeutics' business and its evolving consumer preferences.
- Compare Corcept Therapeutics' performance and market position to its competitors. Analyze how Corcept Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Corcept Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Corcept Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Corcept Therapeutics Incorporated stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Corcept Therapeutics Incorporated is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Corcept Therapeutics Stock
Researching Corcept Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 82.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.61. Corcept Therapeutics had not issued any dividends in recent years.
To determine if Corcept Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Corcept Therapeutics' research are outlined below:
| Corcept Therapeutics had very high historical volatility over the last 90 days | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Why Is Corcept Down 5.3 percent Since Last Earnings Report |
Corcept Therapeutics Quarterly Cash And Short Term Investments |
|
Corcept Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Corcept Therapeutics Incorporated. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Corcept Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Corcept Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Corcept Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-01 | 2017-03-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2016-11-01 | 2016-09-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2015-11-05 | 2015-09-30 | -0.02 | -0.01 | 0.01 | 50 | ||
2015-05-07 | 2015-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2014-11-04 | 2014-09-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2014-03-05 | 2013-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2011-05-04 | 2011-03-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2010-03-25 | 2009-12-31 | -0.1 | -0.09 | 0.01 | 10 |
Know Corcept Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corcept Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corcept Therapeutics Incorporated backward and forwards among themselves. Corcept Therapeutics' institutional investor refers to the entity that pools money to purchase Corcept Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.3 M | First Trust Advisors L.p. | 2024-12-31 | 1.1 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.1 M | Northern Trust Corp | 2024-12-31 | 1 M | Btim Corp | 2024-12-31 | 899.1 K | D. E. Shaw & Co Lp | 2024-12-31 | 886.6 K | Norges Bank | 2024-12-31 | 834.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 796.8 K | Amvescap Plc. | 2024-12-31 | 706.1 K | Blackrock Inc | 2024-12-31 | 15.7 M | Vanguard Group Inc | 2024-12-31 | 10.1 M |
Corcept Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.76 B.Market Cap |
|
Corcept Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.17 | |
| Return On Capital Employed | 0.20 | 0.21 | |
| Return On Assets | 0.17 | 0.17 | |
| Return On Equity | 0.21 | 0.22 |
Determining Corcept Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Corcept Therapeutics is a good buy. For example, gross profit margin measures Corcept Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Corcept Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Corcept Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corcept Therapeutics Incorporated. Check Corcept Therapeutics' Beneish M Score to see the likelihood of Corcept Therapeutics' management manipulating its earnings.
Evaluate Corcept Therapeutics' management efficiency
Corcept Therapeutics has return on total asset (ROA) of 0.1171 % which means that it generated a profit of $0.1171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2381 %, meaning that it created $0.2381 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.17 in 2025. Return On Capital Employed is likely to gain to 0.21 in 2025. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 882.6 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 13.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.58 | 6.91 | |
| Tangible Book Value Per Share | 6.58 | 6.91 | |
| Enterprise Value Over EBITDA | 37.10 | 38.96 | |
| Price Book Value Ratio | 7.65 | 8.04 | |
| Enterprise Value Multiple | 37.10 | 38.96 | |
| Price Fair Value | 7.65 | 8.04 | |
| Enterprise Value | 2.9 B | 3.1 B |
The strategic initiatives led by Corcept Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.612 |
Basic technical analysis of Corcept Stock
As of the 30th of March, Corcept Therapeutics shows the Risk Adjusted Performance of 0.0448, mean deviation of 2.43, and Downside Deviation of 3.13. Corcept Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Corcept Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corcept Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corcept Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corcept Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corcept Therapeutics' Outstanding Corporate Bonds
Corcept Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Corcept Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Corcept bonds can be classified according to their maturity, which is the date when Corcept Therapeutics Incorporated has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Corcept Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Corcept Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0448 | |||
| Market Risk Adjusted Performance | 0.0747 | |||
| Mean Deviation | 2.43 | |||
| Semi Deviation | 3.06 | |||
| Downside Deviation | 3.13 | |||
| Coefficient Of Variation | 2300.36 | |||
| Standard Deviation | 3.48 | |||
| Variance | 12.13 | |||
| Information Ratio | 0.0561 | |||
| Jensen Alpha | 0.259 | |||
| Total Risk Alpha | 0.3598 | |||
| Sortino Ratio | 0.0624 | |||
| Treynor Ratio | 0.0647 | |||
| Maximum Drawdown | 25.08 | |||
| Value At Risk | (4.26) | |||
| Potential Upside | 4.93 | |||
| Downside Variance | 9.79 | |||
| Semi Variance | 9.34 | |||
| Expected Short fall | (2.74) | |||
| Skewness | 0.6348 | |||
| Kurtosis | 4.66 |
| Risk Adjusted Performance | 0.0448 | |||
| Market Risk Adjusted Performance | 0.0747 | |||
| Mean Deviation | 2.43 | |||
| Semi Deviation | 3.06 | |||
| Downside Deviation | 3.13 | |||
| Coefficient Of Variation | 2300.36 | |||
| Standard Deviation | 3.48 | |||
| Variance | 12.13 | |||
| Information Ratio | 0.0561 | |||
| Jensen Alpha | 0.259 | |||
| Total Risk Alpha | 0.3598 | |||
| Sortino Ratio | 0.0624 | |||
| Treynor Ratio | 0.0647 | |||
| Maximum Drawdown | 25.08 | |||
| Value At Risk | (4.26) | |||
| Potential Upside | 4.93 | |||
| Downside Variance | 9.79 | |||
| Semi Variance | 9.34 | |||
| Expected Short fall | (2.74) | |||
| Skewness | 0.6348 | |||
| Kurtosis | 4.66 |
Consider Corcept Therapeutics' intraday indicators
Corcept Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Corcept Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Corcept Therapeutics Corporate Filings
F4 | 26th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of February 2025 Other Reports | ViewVerify | |
F5 | 14th of February 2025 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
Corcept Stock media impact
Far too much social signal, news, headlines, and media speculation about Corcept Therapeutics that are available to investors today. That information is available publicly through Corcept media outlets and privately through word of mouth or via Corcept internal channels. However, regardless of the origin, that massive amount of Corcept data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Corcept Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Corcept Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Corcept Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Corcept Therapeutics alpha.
Corcept Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Corcept Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Corcept Therapeutics Historical Investor Sentiment
Investor biases related to Corcept Therapeutics' public news can be used to forecast risks associated with an investment in Corcept. The trend in average sentiment can be used to explain how an investor holding Corcept can time the market purely based on public headlines and social activities around Corcept Therapeutics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Corcept Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Corcept Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Corcept Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Corcept Therapeutics.
Corcept Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Corcept Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Corcept Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Corcept Therapeutics' options.
Corcept Therapeutics Corporate Management
| Hazel Hunt | Chief Officer | Profile | |
| Amy Flood | Chief Officer | Profile | |
| Joseph MD | President, CoFounder | Profile | |
| William PharmD | Chief Officer | Profile | |
| Gary JD | Chief Secretary | Profile |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.